Hyaluronic Acid (Sodium Hyaluronate) for Dry Eye Disease

Verdict: Oral HA for dry eye: unproven; eye drops work

Hyaluronic acid eye drops are a well-established lubricant for dry eye, but the oral supplement version this verdict covers has not been shown to work: the only human trial is a single small, confounded pilot study, so there is no reliable evidence that swallowing HA helps your eyes.

U ⚫ U Unverified Disputed

🔬Why this grade7-layer evidence engine

This grade is Unverified because of a route mismatch. Nearly all the strong evidence is for topical HA eye drops, not the oral capsule the verdict is about. Two meta-analyses of eye drops (PMID 33804439, n=2,078; PMID 38895674, n=1,796) found modest improvements in tear stability and corneal staining, and head-to-head RCTs (PMID 36333364; PMID 39931678) showed HA drops perform comparably to comparators. Those are a different product entirely.

For oral HA, the cupboard is nearly bare. The single human trial (PMID 31662894) enrolled just 54 people, was open-label, and gave the treatment group oral plus topical HA while controls got topical alone, so any benefit cannot be attributed to the pill. That one confounded pilot cannot establish efficacy, which is why the engine rates the oral route as unverified rather than supported.

Regulators reinforce the caution. The US FDA stopped reviewing the GRAS notice for oral sodium hyaluronate (GRN 976), partly over published reports of possible drug-like effects, and the EU's EFSA has not authorized any health claim for oral HA. Mayo Clinic addresses only injectable HA, while clinic and society endorsements apply specifically to eye drops. Bottom line: use the drops if advised, but do not expect oral HA to treat dry eye.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.70
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
U · Disputed
Confidence
58%
Conflicting evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L11 AI re-checkIndependent read
0.20
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.65
L2 PubMedPrimary literature
0.85
L5 Clinical bodiesAuthoritative stance
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.7
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — | A→B 因 L4 有 ≥1 against | B→U 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
  5. detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Different concentrations of hyaluronic acid eye drops for dry eye syndrome: a systematic review and Meta-analysis
PMID: 38895674 2024 統合分析 n = 1,796
Finding: High-concentration HA significantly improved CFS vs low-concentration (SMD -3.37; 95% CI -5.25 to -1.48; p=0.0005); other outcomes not significantly different between concentrations.
🟢 High quality Effect size: SMD -3.37 (95% CI -5.25 to -1.48) for CFS
View on PubMed
A Meta-Analysis of the Efficacy of Hyaluronic Acid Eye Drops for the Treatment of Dry Eye Syndrome
PMID: 33804439 2021 統合分析 n = 2,078
Finding: HA eye drops significantly improved tear production vs non-HA (SMD 0.18; 95% CI 0.03-0.33); vs saline: Schirmer SMD 0.27 (95% CI 0.05-0.49), TBUT SMD 0.28 (95% CI 0.03-0.52).
🟢 High quality Academic Effect size: SMD 0.18 (Schirmer vs non-HA); SMD 0.27-0.28 vs saline
View on PubMed
A randomized multicenter evaluation of the efficacy of 0.15% hyaluronic acid versus 0.05% cyclosporine A in dry eye syndrome
PMID: 36333364 2022 RCT (open-label) n = 438
Finding: All outcomes (corneal staining, TBUT, SM score, OSDI) improved in all groups; no statistically significant intergroup differences (p>0.05). HA non-inferior to cyclosporine A with better tolerability.
Effect size: Non-inferiority; no significant between-group SMD reported
View on PubMed
A Prospective, Crossover, Randomized, Double-Blind Clinical Study Comparing the Effectiveness and Ocular Comfort of 0.1% and 0.3% Hyaluronic Acid in Patients With Dry Eye Disease
PMID: 39931678 2025 RCT (double-blind) n = 60
Finding: Both concentrations improved dry eye signs/symptoms; 0.3% HA showed a trend toward better TBUT but no statistically significant difference between concentrations (p=0.676).
Effect size: null (no significant intergroup difference)
View on PubMed
Oral Hyaluronic Acid Supplementation for the Treatment of Dry Eye Disease: A Pilot Study
PMID: 31662894 2019 RCT (open-label) n = 54
Finding: Combined oral+topical HA group showed OSDI improvement (61.8 to 42.3; p<0.001), improved TBUT at 1 and 3 months (p=0.005, p=0.012), and improved CFS (p<0.001) vs topical-only control.
🟠 Limited quality Effect size: OSDI delta ~19.5 points; p<0.001
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
At the notifier's request, FDA ceased to evaluate this notice. source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Neutral
公告訂定食品原料「雞冠萃取物(含透明質酸鈉)」及「流行鏈球菌發酵物(含透明質酸鈉)」之使用限制,每日使用量為80毫克以下。 source↗
L5b Mayo Clinic
Not addressed
Mayo Clinic's official drugs-supplements page covers hyaluronic acid only as 'injection route' for osteoarthritis knee pain. Mayo Clinic Connect patient discussions reference HA-containing preservative-free eye drops (e.g., Oasis drops with glycerin and hyaluronic acid) as helpful for dry eyes, and one patient noted oral HA supplementation with anecdotal benefit. No official Mayo Clinic clinica… source↗
L5c Cleveland Clinic
Supportive
L5e Specialty Society (condition-mapped)
Supportive
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-dry-eye-INT-hyaluronic-acid-001 繁體中文版 →